Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Amortization of Deferred Charges (2020 - 2022)

Historic Amortization of Deferred Charges for Insight Molecular Diagnostics (IMDX) over the last 3 years, with Q3 2022 value amounting to $1000.0.

  • Insight Molecular Diagnostics' Amortization of Deferred Charges fell 9230.77% to $1000.0 in Q3 2022 from the same period last year, while for Dec 2022 it was $12000.0, marking a year-over-year decrease of 7857.14%. This contributed to the annual value of $12000.0 for FY2022, which is 7857.14% down from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Amortization of Deferred Charges stood at $1000.0 for Q3 2022, which was down 9230.77% from $4000.0 recorded in Q2 2022.
  • Over the past 5 years, Insight Molecular Diagnostics' Amortization of Deferred Charges peaked at $35000.0 during Q1 2020, and registered a low of $1000.0 during Q3 2022.
  • Moreover, its 3-year median value for Amortization of Deferred Charges was $14000.0 (2021), whereas its average is $15454.5.
  • In the last 5 years, Insight Molecular Diagnostics' Amortization of Deferred Charges crashed by 3636.36% in 2021 and then crashed by 9230.77% in 2022.
  • Quarter analysis of 3 years shows Insight Molecular Diagnostics' Amortization of Deferred Charges stood at $22000.0 in 2020, then crashed by 54.55% to $10000.0 in 2021, then crashed by 90.0% to $1000.0 in 2022.
  • Its last three reported values are $1000.0 in Q3 2022, $4000.0 for Q2 2022, and $7000.0 during Q1 2022.